Key Players in Pharmaceutical Contract Manufacturing

Market developments, outsourcing hotspots and growth strategies
# Table of Contents

**Key Players in Pharmaceutical Contract Manufacturing**

## Executive summary

<table>
<thead>
<tr>
<th>Market development</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalent</td>
<td>12</td>
</tr>
<tr>
<td>Lonza</td>
<td>13</td>
</tr>
<tr>
<td>Boehringer Ingelheim (BI)</td>
<td>14</td>
</tr>
<tr>
<td>DSM</td>
<td>15</td>
</tr>
<tr>
<td>Evonik</td>
<td>15</td>
</tr>
<tr>
<td>Patheon</td>
<td>16</td>
</tr>
<tr>
<td>Piramal</td>
<td>17</td>
</tr>
<tr>
<td>Jubilant</td>
<td>17</td>
</tr>
<tr>
<td>Aenova</td>
<td>18</td>
</tr>
<tr>
<td>Fareva</td>
<td>19</td>
</tr>
</tbody>
</table>

## Chapter 1 Introduction

What is this report about? 22
Methodology 22

## Chapter 2 Market development

<table>
<thead>
<tr>
<th>Summary</th>
<th>26</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview</td>
<td>27</td>
</tr>
<tr>
<td>Market size and growth</td>
<td>27</td>
</tr>
<tr>
<td>Positioning and performance of leading players</td>
<td>27</td>
</tr>
<tr>
<td>Drivers of manufacturing outsourcing</td>
<td>29</td>
</tr>
<tr>
<td>Key trends in the market</td>
<td>30</td>
</tr>
<tr>
<td>Increasing offshore outsourcing by Big Pharma</td>
<td>30</td>
</tr>
<tr>
<td>Expansion of biopharmaceutical contract manufacturing</td>
<td>30</td>
</tr>
<tr>
<td>Industry consolidation</td>
<td>31</td>
</tr>
</tbody>
</table>
Chapter 3  
**Catalent**

Summary  
Company overview  
Group structure  
Oral Technologies  
Sterile Technologies  
Packaging Services  
Recent financial performance  
Performance by business segments  
Oral Technologies  
Sterile Technologies  
Packaging Services  
Performance by geographies  
Manufacturing and R&D  
Acquisitions and divestments  
Growth strategies

Chapter 4  
**Lonza**

Summary  
Company overview  
Group structure  
Life Science Ingredients  
Exclusive Synthesis & Biopharmaceuticals  
Bioscience  
Recent financial performance
Chapter 5  Boehringer Ingelheim (BI)  64

Summary  64
Company overview  65
Group structure  65
Biopharmaceuticals  65
Pharmaceuticals Production  66
Pharma Chemicals  66
Recent financial performance  66
Performance by business segments  67
Manufacturing and R&D  68
Acquisitions and divestments  69
Growth strategies  69
Capacity expansion  69
Strategic partnerships  69

Chapter 6  Royal DSM (DSM)  72

Summary  72
Company overview  73
Group structure  73
Recent financial performance  74
Manufacturing and R&D  76
Acquisitions and divestments  76
Growth strategies  77

Chapter 7  Evonik (Degussa)  80

Summary  80
Chapter 8  Patheon

Summary 88
Company overview 89
Group structure 89
Commercial Manufacturing 89
Pharmaceutical Development Services (PDS) 89
Recent financial performance 90
Performance by business segments 91
Performance by geographies 92
Manufacturing and R&D 93
Acquisitions and divestments 93
Growth strategies 94
Focus on prescription drugs business 94
Improve profitability and capacity utilization 94
Diversify customer base 94

Chapter 9  Piramal Healthcare (Piramal) 96

Summary 96
Company overview 97
Group structure 97
PDS (Pharmaceutical Development Services) 97
PMS (Pharmaceutical Manufacturing Services) 98
MMBB (Manufacturing Molecules/Building Blocks) 98
Others 98
Recent financial performance 98
Performance by business segments 100
Manufacturing and R&D 100
Acquisitions and divestments 101
Growth strategies 101

Chapter 10  Jubilant Organosys (Jubilant) 104

Summary 104
Company overview 105
Group structure 105
Recent financial performance 106
Performance by product segments 107
Performance by geographies 108
Manufacturing and R&D 110
Acquisitions and divestments 110
Growth strategies 111

Chapter 11  Aenova 114

Summary 114
Company overview 115
Group structure 115
Swiss Caps 115
Dragenopharm 115
Recent financial performance 116
Manufacturing and R&D 116
Acquisitions and divestments 117
Growth strategies 117

Chapter 12  Fareva 120

Summary 120
Company overview 121
Group structure 121
Recent financial performance 122
Manufacturing and R&D 123
Acquisitions and divestments 123
Growth strategies 124
Chapter 13  11 to 20 Companies

Nipro  126
Company overview  126
Recent financial performance  127

Siegfried  128
Company description  128
Recent financial performance  129

Haupt  130
Company description  130
Recent financial performance  131

Divi’s Laboratories (Divi’s)  132
Company description  132
Recent financial performance  133

Cambrex  134
Company description  134
Recent financial performance  134

Recipharm  135
Company description  135
Recent financial performance  136

Archimica  137
Company description  137

Vetter  138
Company description  138

Famar  139
Company description  139

NextPharma  141
Company description  141

Other contract manufacturers  142

Index  143
List of Figures

- Figure 2.1: Global pharmaceutical contract manufacturing market size, 2007-2011
- Figure 2.2: Positioning of leading players (2007)*
- Figure 2.3: Labor cost in select countries
- Figure 2.4: No. of FDA approved plants outside the US, 2007
- Figure 3.5: Catalent’s financial performance ($m), 2004-2008*
- Figure 3.6: Catalent’s revenue break-up by geography (%), 2008
- Figure 4.7: Lonza’s contract manufacturing financial performance ($m), 2005-2007*
- Figure 5.8: BI Industrial Customers’ financial performance ($m), 2005-2007*
- Figure 6.9: DSM DPP’s financial performance ($m), 2005-2007*
- Figure 7.10: Evonik’s Health & Nutrition financial performance ($m), 2006-2007*
- Figure 8.11: Patheon’s financial performance ($m), 2006-2008*
- Figure 8.12: Patheon’s Commercial Manufacturing revenue break-up by geography (%), 2008*
- Figure 9.13: Piramal Pharma Solutions’ financial performance ($m), 2006-2007*
- Figure 10.14: Jubilant’s CRAMS financial performance ($m), 2003-2007*
- Figure 10.15: Jubilant’s revenue break-up by geography (%), 2007*
- Figure 12.16: Fareva Pharmaceuticals’ financial performance ($m), 2006-2008*

List of Tables

- Table 2.1: Leading pharmaceutical contract manufacturing companies, 2007
- Table 2.2: Select manufacturing outsourcing initiatives planned by the Big Pharma
- Table 2.3: Leading CMOs in India
- Table 2.4: Select foreign acquisitions by Indian players
- Table 2.5: Manufacturing cost comparison
- Table 3.6: Catalent’s snapshot
- Table 3.7: Catalent’s financial performance ($m), 2004-2008
- Table 3.8: Catalent’s business segments performance ($m), 2006-2008
- Table 3.9: Catalent’s performance by geography ($m), 2006–2008
- Table 4.10: Lonza’s snapshot
- Table 4.11: Lonza’s contract manufacturing financial performance ($m), 2005-2007
- Table 4.12: Lonza’s contract manufacturing business segments performance ($m), 2005-2007
- Table 5.13: BI’s snapshot
- Table 5.14: BI Industrial Customers’ financial performance ($m), 2005-2007
- Table 5.15: BI Industrial Customers’ business segments performance ($m), 2005-2007
- Table 6.16: DSM’s snapshot
- Table 6.17: DSM DPP’s financial performance ($m), 2005-2007
- Table 7.18: Evonik’s snapshot
- Table 7.19: Evonik’s Health & Nutrition financial performance ($m), 2006-2007
- Table 8.20: Patheon’s snapshot
- Table 8.21: Patheon’s financial performance ($m), 2006-2008
- Table 8.22: Patheon’s business segments performance ($m), 2008
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.23</td>
<td>Patheon’s Commercial Manufacturing performance by geography ($m), 2007–2008</td>
<td>93</td>
</tr>
<tr>
<td>9.24</td>
<td>Piramal’s snapshot</td>
<td>96</td>
</tr>
<tr>
<td>9.26</td>
<td>Piramal Pharma Solutions’ business segments performance ($m), 2005-2007</td>
<td>100</td>
</tr>
<tr>
<td>10.27</td>
<td>Jubilant’s snapshot</td>
<td>104</td>
</tr>
<tr>
<td>10.28</td>
<td>Jubilant’s CRAMS financial performance ($m), 2003-2007</td>
<td>107</td>
</tr>
<tr>
<td>10.29</td>
<td>Jubilant’s CRAMS product segments performance ($m), 2006-2007</td>
<td>108</td>
</tr>
<tr>
<td>10.30</td>
<td>Jubilant’s performance by geography ($m), 2005–2007</td>
<td>109</td>
</tr>
<tr>
<td>11.31</td>
<td>Aenova’s snapshot</td>
<td>114</td>
</tr>
<tr>
<td>12.32</td>
<td>Fareva’s snapshot</td>
<td>120</td>
</tr>
<tr>
<td>12.33</td>
<td>Fareva Pharmaceuticals’ financial performance ($m), 2006-2008</td>
<td>123</td>
</tr>
<tr>
<td>13.34</td>
<td>Nipro’s snapshot</td>
<td>126</td>
</tr>
<tr>
<td>13.35</td>
<td>Nipro’s Pharmaceutical financial performance ($m), 2003-2007 *</td>
<td>127</td>
</tr>
<tr>
<td>13.36</td>
<td>Siegfried’s snapshot</td>
<td>128</td>
</tr>
<tr>
<td>13.37</td>
<td>Siegfried’s financial performance ($m), 2006-2007*</td>
<td>129</td>
</tr>
<tr>
<td>13.38</td>
<td>Haupt’s snapshot</td>
<td>130</td>
</tr>
<tr>
<td>13.39</td>
<td>Divi’s’ snapshot</td>
<td>132</td>
</tr>
<tr>
<td>13.40</td>
<td>Divi’s financial performance ($m), 2003-2007</td>
<td>133</td>
</tr>
<tr>
<td>13.41</td>
<td>Cambrex’s snapshot</td>
<td>134</td>
</tr>
<tr>
<td>13.42</td>
<td>Cambrex’s financial performance ($m), 2005-2007*</td>
<td>135</td>
</tr>
<tr>
<td>13.43</td>
<td>Recipharm’s snapshot</td>
<td>135</td>
</tr>
<tr>
<td>13.44</td>
<td>Recipharm’s financial performance ($m), 2003-2008</td>
<td>136</td>
</tr>
<tr>
<td>13.45</td>
<td>Archimica’s snapshot</td>
<td>137</td>
</tr>
<tr>
<td>13.46</td>
<td>Vetter’s snapshot</td>
<td>138</td>
</tr>
<tr>
<td>13.47</td>
<td>Famar’s snapshot</td>
<td>139</td>
</tr>
<tr>
<td>13.48</td>
<td>NextPharma’s snapshot</td>
<td>141</td>
</tr>
<tr>
<td>13.49</td>
<td>Other select contract manufacturers</td>
<td>142</td>
</tr>
</tbody>
</table>